Nelon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 06-07-2024
- Paid Up Capital ₹ 1.00 M
as on 06-07-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 M
as on 06-07-2024
- Revenue %
(FY 2022)
- Profit -71.96%
(FY 2022)
- Ebitda -364.52%
(FY 2022)
- Net Worth -1.08%
(FY 2022)
- Total Assets -0.23%
(FY 2022)
About Nelon Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.50 M.
Parveen Kumar and Balinder Singh serve as directors at the Company.
- CIN/LLPIN
U24239HR2007PTC036581
- Company No.
036581
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Feb 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Kurukshetra, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nelon Pharmaceuticals Private Limited offer?
Nelon Pharmaceuticals Private Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Vitamin & Multivitamin Injections, Methylcobalamin Injection, Pharmaceutical Medicine, Lycopene Capsule, Antipyretic Medication, Paracetamol Suspension, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Nelon Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parveen Kumar  | Director | 05-Feb-2007 | Current |
| Balinder Singh | Director | 05-Feb-2007 | Current |
Financial Performance of Nelon Pharmaceuticals.
Nelon Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 71.96% decrease in profit. The company's net worth dipped by a decrease of 1.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nelon Pharmaceuticals?
Unlock access to Nelon Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 31 Jan 2013 | ₹1.50 M | Open |
How Many Employees Work at Nelon Pharmaceuticals?
Unlock and access historical data on people associated with Nelon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nelon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nelon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
